Differential uptake of prostate-specific antigen testing in the US and UK has been linked to between-country differences for prostate cancer incidence. We examined stage-specific fatal prostate cancer incidence trends in the US and England, by treatment and race/ethnicity.
Using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program and Public Health England’s National Cancer Registration and Analysis Service, we identified prostate cancer patients diagnosed between 1995 and 2005, aged 45–84 years. Fatal prostate cancer was defined as death attributed to the disease within 10 years of diagnosis. We used age–period–cohort models to assess trends in fatal prostate cancer incidence.
Fatal prostate cancer incidence declined in the US by −7.5% each year and increased in England by 7.7% annually. These trends were primarily driven by locoregional disease in the US and distant disease in England. Black men in both countries had twofold to threefold higher fatal prostate cancer incidence rates, when compared with their white counterparts; however, receipt of radical prostatectomy lessened this disparity.
We report a significant increasing rate of fatal prostate cancer incidence among English men. The black–white racial disparity appears pervasive but is attenuated among those who received radical prostatectomy in the US.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kelly, S. P., Rosenberg, P. S., Anderson, W. F., Andreotti, G., Younes, N., Cleary, S. D. et al. Trends in the incidence of fatal prostate cancer in the United States by race. Eur. Urol. 71, 195–201 (2017).
Epstein, M. M., Edgren, G., Rider, J. R., Mucci, L. A. & Adami, H. O. Temporal trends in cause of death among Swedish and US men with prostate cancer. J. Natl Cancer Inst. 104, 1335–1342 (2012).
Andriole, G. L. Serum prostate-specific antigen: the most useful tumor marker. J. Clin. Oncol. 10, 1205–1207 (1992).
Lu-Yao, G. L., Friedman, M. & Yao, S. L. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J. Urol. 157, 2219–2222 (1997).
Sheikh, K. & Bullock, C. Rise and fall of radical prostatectomy rates from 1989 to 1996. Urology 59, 378–382 (2002).
Collin, S. M., Martin, R. M., Metcalfe, C., Gunnell, D., Albertsen, P. C., Neal, D. et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 9, 445–452 (2008).
Martin, R. M., Donovan, J. L., Turner, E. L., Metcalfe, C., Young, G. J., Walsh, E. I. et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP Randomized clinical trial. JAMA 319, 883–895 (2018).
Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., Nelen, V. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320–1328 (2009).
Andriole, G. L., Crawford, E. D., Grubb, R. L. 3rd, Buys, S. S., Chia, D., Church, T. R. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).
Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H. et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J. Natl Cancer Inst. 94, 981–990 (2002).
Force, U. S. P. S. T., Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B. et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA 319, 1901–1913 (2018).
Patel, N. H., Bloom, J., Hillelsohn, J., Fullerton, S., Allman, D., Matthews, G. et al. Prostate cancer screening trends after United States Preventative Services Task Force Guidelines in an underserved population. Health Equity 2, 55–61 (2018).
Melia, J., Moss, S. & Johns, L. Contributors in the participating l. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 94, 51–56 (2004).
Williams, N., Hughes, L. J., Turner, E. L., Donovan, J. L., Hamdy, F. C., Neal, D. E. et al. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int. 108, 1402–1408 (2011).
Melia, J. & Moss, S. Survey of the rate of PSA testing in general practice. Br. J. Cancer 85, 656–657 (2001).
Hall, I. J., Tangka, F. K. L., Sabatino, S. A., Thompson, T. D., Graubard, B. I. & Breen, N. Patterns and trends in cancer screening in the United States. Prev. Chronic Dis. 15, E97 (2018).
Smittenaar, C. R., Petersen, K. A., Stewart, K. & Moitt, N. Cancer incidence and mortality projections in the UK until 2035. Br. J. Cancer 115, 1147–1155 (2016).
Jack, R. H., Davies, E. A. & Moller, H. Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South-East England. BJU Int. 105, 1226–1230 (2010).
Cook, M. B., Rosenberg, P. S., McCarty, F. A., Wu, M., King, J., Eheman, C. et al. Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008. Prostate 75, 758–763 (2015).
Ben-Shlomo, Y., Evans, S., Ibrahim, F., Patel, B., Anson, K., Chinegwundoh, F. et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur. Urol. 53, 99–105 (2008).
National Cancer Institute, DCCPS, Surveillance Research Program. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2017 Sub (1973-2015) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2016 Counties. https://seer.cancer.gov/data-software/documentation/seerstat/nov2017/ (2018).
National Disease Registration Service. https://www.ndrs.nhs.uk/. (2018). Accessed 6 Dec 2018.
van Buuren, S. & Groothuis-Oudshoorn, K. mice: Multivariate imputation by chained equations in R. J. Stat. Softw. 45, 1–67 (2011).
Rubin, D. B. Multiple Imputation for Nonresponse in Surveys (John Wiley and Sons, New York, 1987).
Ahmad, O. B., Boschi-Pinto, C., Lopez, A. D., Murray, C. J. L., Lozano, R. & Inoue, M. Age Standardization of Rates: A New WHO Standard (World Health Organization, Geneva, 2001).
Kim, H. J., Fay, M. P., Feuer, E. J. & Midthune, D. N. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19, 335–351 (2000).
Rosenberg, P. S. & Anderson, W. F. Age-period-cohort models in cancer surveillance research: ready for prime time? Cancer Epidemiol. Biomark. Prev. 20, 1263–1268 (2011).
Holford, T. R. The estimation of age, period and cohort effects for vital rates. Biometrics 39, 311–324 (1983).
Rosenberg, P. S. & Anderson, W. F. Proportional hazards models and age-period-cohort analysis of cancer rates. Stat. Med. 29, 1228–1238 (2010).
Rosenberg, P. S., Barker, K. A. & Anderson, W. F. Estrogen receptor status and the future burden of invasive and in situ breast cancers in the United States. J. Natl Cancer Inst. 107, djv159 (2015)
Pashayan, N., Powles, J., Brown, C. & Duffy, S. W. Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing. Br. J. Cancer 95, 398–400 (2006).
Moller, H., Fairley, L., Coupland, V., Okello, C., Green, M., Forman, D. et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br. J. Cancer 96, 1484–1488 (2007).
Tikkinen, K. A. O., Dahm, P., Lytvyn, L., Heen, A. F., Vernooij, R. W. M., Siemieniuk, R. A. C. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ 362, k3581 (2018).
Wallner, L., Frencher, S., Hsu, J. W., Loo, R., Huang, J., Nichol, M. et al. Prostate cancer screening trends in a large, integrated health care system. Perm. J. 16, 4–9 (2012).
Sirovich, B. E., Schwartz, L. M. & Woloshin, S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 289, 1414–1420 (2003).
Etzioni, R., Gulati, R., Mallinger, L. & Mandelblatt, J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann. Intern. Med. 158, 831–838 (2013).
Fleshner, K., Carlsson, S. V. & Roobol, M. J. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat. Rev. Urol. 14, 26–37 (2017).
Dess, R. T., Hartman, H. E., Mahal, B. A., Soni, P. D., Jackson, W. C., Cooperberg, M. R. et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 5, 975–983 (2019).
Paller, C. J., Wang, L. & Brawley, O. W. Racial inequality in prostate cancer outcomes-socioeconomics, not biology. JAMA Oncol. 5, 983–984 (2019).
The authors acknowledge and thank the teams at the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. Data for this study are based on information collected and quality assured by the PHE National Cancer Registration and Analysis Service. Access to the data was facilitated by the PHE Office for Data Release.
Ethics approval and consent to participate
NIH OHSRP determined that this research activity was exempt from IRB review per 45 CFR 46.
The cancer registry data from the United States is available upon request to the Surveillance, Epidemiology, and End Results Program and can be reached at email@example.com. Inquiries for England’s cancer registration data can be made to Public Health England’s Office for Data Release at ODR@phe.gov.uk.
The authors declare no competing interests.
This work was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Butler, E.N., Kelly, S.P., Coupland, V.H. et al. Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment. Br J Cancer 123, 487–494 (2020). https://doi.org/10.1038/s41416-020-0859-x
An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment
European Urology (2021)
Impedimetric aptamer-based glycan PSA score for discrimination of prostate cancer from other prostate diseases
Biosensors and Bioelectronics (2021)